Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer
The firm envisions marketing the 53-gene signature with its existing MammaPrint and BluePrint tests as a comprehensive platform for breast cancer treatment selection.
FDA Approves Lynparza as Adjuvant Therapy With Myriad Genetics CDx for BRCA-Mutated Breast Cancer
Updated data from the pivotal OlympiA trial that led the drug's approval shows AstraZeneca and Merck's PARP inhibitor improves survival compared to placebo.
FDA Approves Foundation Medicine Test as CDx for Merck's Keytruda to Identify MSI-H Solid Tumors
The FoundationOne CDx test can now be used as a companion diagnostic for the drug to identify patients with solid tumors that have high microsatellite instability.
In Brief This Week: PerkinElmer, Chembio, Becton Dickinson, Fulgent Genetics, and More
News items for the in vitro diagnostic industry for the week of Sept. 20, 2021.
Illumina, Merck Partner to Advance Homologous Recombination Deficiency CDx, Research Assay
Under the terms of the deal, Illumina will develop a new HRD CDx for the EU and UK markets and a research-use only HRD assay that will be add-on content for its TSO 500 panel.